Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer

OBJECTIVE: Preclinical evidence and early clinical trials have demonstrated the activity of SPL-108, a targeted agent that inhibits CD44 mediated induction of multidrug resistance specifically to paclitaxel and platinum agents. We conducted a phase I, open label, dose escalation study of the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Girda, Eugenia, Hou, June, Nelson, David, Finlayson, Malcolm, de Meritens, Alexandre Buckley, Chekmareiva, Marina, Leiser, Aliza, Song, Mihae, Stephenson, Ruth, Chan, Nancy, Tergas, Ana I, Vattakalam, Reena, Wright, Jason D, Yu, Hua, Martincuks, Antons, Kohut, Adrian, Palmer, Joycelynne, Rodriguez-Rodriguez, Lorna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380511/
https://www.ncbi.nlm.nih.gov/pubmed/35750354
http://dx.doi.org/10.1136/ijgc-2021-003316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380511/
https://www.ncbi.nlm.nih.gov/pubmed/35750354
http://dx.doi.org/10.1136/ijgc-2021-003316

Ejemplares similares